ICLR
Icon
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ICLR
Icon Public Limited Company
A world-leading provider of contract clinical research services to the pharmaceutical, biotechnology and medical device
Life Science Tools and Services
Invalid Date
02/04/2013
NASDAQ Stock Exchange
41900
12-31
Common stock
South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
--
Icon Public Limited Company is a contract research organization (" CRO ") that provides outsourced development services to the pharmaceutical, biotechnology and medical device industries on a global scale. The company specializes in strategic development, management and project analysis, which support the entire clinical development process, ranging from compound selection to Phase I to Phase IV clinical studies. The company began operations in 1990. The CRO industry provides separate product development services to the pharmaceutical, biotechnology and medical device industries. Companies in these industries outsource product development services to contract research organizations to more effectively manage the drug development process and maximize the profit potential of patent-protected and generic products at a lower cost. The contract research organization industry has evolved from a small number of companies providing limited clinical services in the 1970s to a large number of contract research organizations providing a wide range of overall research and development processes (including preclinical development, clinical trial management, clinical data management, research design, biological data analysis, aftermarket supervision, regulatory affairs services and central laboratory services). Contract research organizations are subject to applicable regulatory authorities and are required to provide these services in line with better clinical and laboratory practice.
Company Financials
EPS
ICLR has released its 2024 Q4 earnings. EPS was reported at 3.43, versus the expected 3.43, meeting expectations. The chart below visualizes how ICLR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICLR has released its 2024 Q4 earnings report, with revenue of 2.04B, reflecting a YoY change of -1.22%, and net profit of 260.00M, showing a YoY change of 20.14%. The Sankey diagram below clearly presents ICLR’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
